Literature DB >> 3062845

Effect of glicentin-related peptides upon the secretion of insulin and glucagon in the canine pancreas.

A Ohneda1, M Ohneda.   

Abstract

In order to clarify responses of the endocrine pancreas to glicentin, four glicentin-related peptides were investigated in a local circulation preparation of the canine pancreas. These peptides were administered in a dosage of 200 pmole for 10 min into the pancreaticoduodenal artery under the continuous infusion of 0.5% arginine solution. In a group of six dogs, the administration of glicentin-related pancreatic peptide (GRPP) and glicentin 1-16 resulted in an increase in plasma insulin (IRI) and a decrease in plasma glucagon (IRG). In the other group of six dogs, the administration of glicentin 62-69 induced an increase in plasma IRI and a decrease in plasma IRG. Following the successive infusion of oxyntomodulin, both plasma IRI and IRG increased slightly. Porcine glucagon administered at the end of each experiment exerted a rise in blood glucose and plasma IRI in addition to an increase in plasma IRG. In comparison of the maximal responses of plasma IRI and IRG to these glicentin-related peptides, the administration of glicentin 1-16, 62-69 or GRPP elicited an increase in plasma IRI and a decrease in plasma IRG. In contrast, oxyntomodulin and glucagon increased both plasma IRI and IRG. The present study indicates that glicentin-related peptides, both the N- and C-terminal portions, affect the endocrine function of the pancreas and suggests that glicentin released by nutrient ingestion plays an important role in the enteroinsular axis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062845     DOI: 10.1620/tjem.155.197

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  7 in total

1.  Fasting Circulating Glicentin Increases After Bariatric Surgery.

Authors:  Juliette Raffort; Patricia Panaïa-Ferrari; Fabien Lareyre; Pascale Bayer; Pascal Staccini; Patrick Fénichel; Giulia Chinetti
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

2.  Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

Authors:  Nicolai J Wewer Albrechtsen; Bolette Hartmann; Simon Veedfald; Johanne A Windeløv; Astrid Plamboeck; Kirstine N Bojsen-Møller; Thomas Idorn; Bo Feldt-Rasmussen; Filip K Knop; Tina Vilsbøll; Sten Madsbad; Carolyn F Deacon; Jens J Holst
Journal:  Diabetologia       Date:  2014-06-03       Impact factor: 10.122

Review 3.  Insights on glicentin, a promising peptide of the proglucagon family.

Authors:  Juliette Raffort; Fabien Lareyre; Damien Massalou; Patrick Fénichel; Patricia Panaïa-Ferrari; Giulia Chinetti
Journal:  Biochem Med (Zagreb)       Date:  2017-06-15       Impact factor: 2.313

Review 4.  Glucagon Control on Food Intake and Energy Balance.

Authors:  Omar Al-Massadi; Johan Fernø; Carlos Diéguez; Ruben Nogueiras; Mar Quiñones
Journal:  Int J Mol Sci       Date:  2019-08-11       Impact factor: 5.923

Review 5.  Proglucagon-Derived Peptides as Therapeutics.

Authors:  Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

6.  Glicentin-related pancreatic polypeptide inhibits glucose-stimulated insulin secretion from the isolated pancreas of adult male rats.

Authors:  Lynda Whiting; Kevin W Stewart; Deborah L Hay; Paul W Harris; Yee S Choong; Anthony R J Phillips; Margaret A Brimble; Garth J S Cooper
Journal:  Physiol Rep       Date:  2015-12

Review 7.  The Enigmatic N-Terminal Domain of Proglucagon; A Historical Perspective.

Authors:  J Michael Conlon
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-11       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.